Suprefact 1mg/Ml Injection
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Suprefact* 1mg/ml Injection.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Suprefact Injection contains 1.00mg buserelin as buserelin acetate in 1ml aqueous solution.
1.00mg buserelin is equivalent to 1.05mg buserelin acetate.
Suprefact Injection also contains 10mg benzyl alcohol in 1ml aqueous solution.
For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Injection.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the treatment of advanced hormone dependent prostatic carcinoma (stage C or stage D according to the classification of Murphy et al, in Cancer 45, p1889-95, 1980) in which suppression of testosterone is indicated; however, not after bilateral orchiectomy (no further reduction of testosterone level by buserelin to be expected).
Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotropin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.
4.2 Posology and method of administration
Initiation of therapy: is most conveniently carried out in hospital; 0.5ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days.
Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact. (see literature for dosage).
4.3 Contraindications
Buserelin should not be used if the tumour is found to be insensitive to hormone manipulation or after surgical removal of the testes. It is contraindicated in cases of known hypersensitivity to LHRH, buserelin or any of the excipients. It should not be used during pregnancy or lactation (see section 4.6 Pregnancy and lactation).
Because of the content of benzyl alcohol Suprefact Injection must not be given to newborns or premature neonates.
Contains 10mg benzyl alcohol in 1ml aqueous solution.
4.4 Special warnings and precautions for use
There is an increased risk of incident depression (which may be severe) in patients undergoing treatment with GnRH agonists, such as Buserelin. Patients should be informed accordingly and treated as appropriate if symptoms occur. Patients with a history of depression must be carefully monitored and treated if necessary during treatment with Suprefact (risk of recurrence or worsening of depression).
In patients with hypertension, blood pressure must be monitored regularly (risk of deterioration of blood pressure levels).
QT Prolongation
Androgen deprivation therapy may prolong the QT interval.
In patients with a history of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval (see section 4.5) physicians should assess the benefit risk ratio including the potential for Torsade de pointes prior to initiating Suprefact.
The use of LHRH-agonists may be associated with decreased bone density and may lead to osteoporosis and an increased risk of bone fracture (see section 4.8). Particular caution is necessary in patients with additional risk factors for osteoporosis (e.g. chronic alcohol abuse, smokers, long-term therapy with anticonvulsants or corticosteroids or a family history of osteoporosis) It is recommended to periodically monitor bone mineral density (BMD) and use preventative measures during therapy to prevent osteopenia/osteoporosis.
In some patients treated with GnRH-agonists, change in glucose tolerance is observed (see section 4.8). In diabetic patients blood glucose levels must be checked regularly (risk of deterioration of metabolic control).
The effect can be monitored clinically and by determination of prostate specific antigen (PSA) and testosterone in the serum. Testosterone levels increases in the beginning of the treatment and thereafter decreases during two weeks. After two to four weeks, the testosterone levels have decreased to castration level.
Disease flare (temporary deterioration of the patient’s condition) has been reported at the beginning of the treatment. The incidence is variable, but of the order of the 10%. Symptoms are usually confined to transient increase in pain, but the exact nature depends on the site of the lesions.
Disease flare is prevented by the prophylactic use of an anti-androgen so it is strongly recommended that administration of an anti-androgen be started as adjunctive therapy (e.g. cyproterone acetate, 300 mg daily) about 5 days before starting treatment. This adjunctive therapy must be continued in parallel with buserelin therapy for 3 to 4 weeks. After this time testosterone levels have usually fallen into the desired range in response to buserelin.
Neurological sequelae have been reported where secondary deposits impinge upon the spinal cord or CNS. In patients with known metastases, e.g. of the spinal column, this adjunctive therapy with an anti-androgen is indispensable to prevent initial complications up to and including , for example, spinal compression and paralysis, arising from a transient activation of the tumour and its metastases (see section 4.8).
Published epidemiological studies suggest a relationship between gonadotrophin releasing hormone (GnRH) agonist treatment and increased risk of cardiovascular disease (such as myocardial infarction, sudden cardiac death, and stroke) and diabetes mellitus. These risks should be evaluated before initiating and during therapy, and patients should be monitored and treated accordingly.
Due to testosterone suppression, GnRH agonist therapy may increase the risk of anaemia. Patients should be evaluated for this risk and managed accordingly.
Once testosterone levels have started to fall below their baseline concentration clinical improvement should start to become apparent. If testosterone levels do not reach the therapeutic range within 4 weeks (6 weeks at the latest) the dose schedule should be checked to be sure that it is being followed exactly. It is unlikely that a patient who is taking the full dose will not show a suppression of testosterone to the therapeutic range. If this is the case, alternative therapy should be considered.
After the initial determination, testosterone levels should be monitored at 3-monthly intervals. A proportion of patients will have tumours that are not
sensitive to hormone manipulation. Absence of clinical improvement in the face of adequate testosterone suppression is diagnostic of this condition, which will not benefit from further therapy with buserelin.
The administration of medications containing benzyl alcohol to newborns or premature neonates has been associated with fatal ‘Gasping Syndrome’ (symptoms include a striking onset of gasping syndrome, hypotension, bradycardia, and cardio-vascular collapse). As benzyl alcohol may cross the placenta, solution for injection should be used with caution in pregnancy.
4.5 Interaction with other medicinal products and other forms of interaction
During treatment with Suprefact, the effect of antidiabetic agents may be attenuated (see section 4.8).
Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Suprefact with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated (see section 4.4).
4.6 Pregnancy and lactation
Suprafact is contraindicated in pregnancy. It is intended for the treatment of advanced prostatic carcinoma, it should not be used in pregnant or lactating women (see 4.3 Contraindications).
Buserelin passed into breast milk in small amounts. Although negative effects on the infant have not been observed, it is recommended that breast-feeding be avoided during treatment with Suprefact in order to prevent the infant from ingesting small quantities of buserelin with breast milk.
4.7 Effects on ability to drive and use machines
Certain adverse effects (eg.dizziness) may impair the ability to concentrate and react, and therefore constitute a risk in situations where these abilities are of special importance (eg. Operating a vehicle or machinery).
4.8 Undesirable effects
The following CIOMS frequency rating is used: Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1000 to <1/100); rare (>1/10 000 to <1/1000); very rare (<1/10 000), not known (cannot be estimated from the available data).
In isolated cases severe hypersensitivity reactions with shock can occur. These may become manifest as reddening of the skin, itching, skin rashes (including urticaria) and allergic asthma with dyspnoea as well as, in isolated cases leading to anaphylactic / anaphylactoid shock.
After administration of the injection, pain or local reaction at the injection site is possible.
At the beginning of treatment, a transient rise in the serum testosterone level usually develops and may lead to temporary activation of the tumour with secondary reactions such as:
- occurrence of exacerbation of bone pain in patients with metastases.
- signs of neurological deficit due to tumour compression with eg. muscle weakness in the legs.
- impaired micturition, hydronephrosis or lymphostasis.
- thrombosis with pulmonary embolism.
Such reactions can be largely avoided when an anti-androgen is given concomitantly in the initial phase of buserelin treatment (see section 4.4 Precautions and Warnings). However, even with concomitant anti-androgen therapy, a mild but transient increase in tumour pain as well as a deterioration in general well being may develop in some patients.
Suprefact treatment may also lead to:
Neoplasms benign and malignant - Very rare cases of pituitary adenomas were reported during treatment with LH-RH agonists, including buserelin.
Blood disorders - Very rare cases of thrombocytopenia or leucopenia.
Metabolism and nutrition disorders - Frequent increase or decrease in weight Occasional changes in appetite and increased thirst. Rarely increase or decrease in blood lipid levels. Very rarely, reduction in glucose tolerance which may lead to the worsening of metabolic control in diabetics.
Psychiatric disorders - Frequent nervousness, emotional instability.
Occasional anxiety, depression or worsening of existing depression.
Mood changes, depression. Frequency: Long term use: Common
Short term use: Uncommon
Nervous system disorders - Dizziness, headache, sleep disturbances, tiredness, drowsiness. Occasional paraesthesia (especially in the arms or legs), disturbances of memory and concentration.
Eye disorders - Occasional dry eyes (possibly leading to eye irritations in people who wear contact lenses), impaired vision (eg blurred vision), feeling of pressure behind the eyes.
Ear and labyrinth disorders - Rare cases of tinnitus, hearing disorders found.
Cardiac disorders - Frequent palpitations.
Frequency unknown: QT prolongation (see sections 4.4 and 4.5)
Vascular disorders - Occasional oedema (of face and extremities) and hot flushes. Very rare cases of a deterioration of blood pressure levels in patients with hypertension.
Gastrointestinal disorders - Frequent lower abdominal pain, stomach ache, nausea, vomiting, diarrhoea, constipation.
Hepato-biliary disorders - Occasional, increase in serum liver enzyme levels (e.g. transaminases), increase in serum bilirubin.
Skin and subcutaneous tissue disorders - Frequent dry skin, acne, increase or decrease in scalp hair (alopecia, hirsutism). Occasional increase or decrease in body hair, splitting nails.
Musculoskeletal and bone disorders - Frequent musculoskeletal discomfort and pain (including shoulder pain/stiffness). The use of LHRH-agonists may be associated with decreased bone density and may lead to osteoporosis and an increased risk of bone fracture. The risk of skeletal fracture increases with the duration of therapy.
Reproductive system and breast disorders - Occasional gynaecomastia (increase in breast size) which is usually painless, atrophy of the testes, decrease in libido and potency (in most patients; result of hormone deprivation).
Most of the effects listed above are directly or indirectly related to the suppression of testosterone by buserelin (symptoms of androgen deficiency).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
Overdose may lead to signs and symptoms such as asthenia, headache, nervousness, hot flushes, dizziness, nausea, abdominal pain, oedemas of the lower extremities, and mastodynia as well as to local reactions at the injection site such as pain, haemorrhage and induration (see section 4.8). Treatment should be symptomatic.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Buserelin is a synthetic peptide. It is a superactive analogue of natural gonadotrophin releasing hormone (gonadorelin, LHRH or GNRH). After an initial stimulation of gonodotrophin release, it down-regulates the hypothalamic-pituitary-gonadal axis.
5.2 Pharmacokinetic properties
Metabolic inactivation by peptidases occurs in the liver and kidney. the drug is also inactivated by pituitary membrane enzymes. The drug is also inactivated by pituitary membrane enzymes.
5.3 Preclinical safety data
None stated.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sodium Chloride
Sodium Dihydrogen Phosphate
Sodium Hydroxide
Benzyl Alcohol
Water for injections
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
Unopened: 2 years.
Once opened use within 15 days.
6.4 Special precautions for storage
Do not store above 25°C. Do not freeze. Keep the vials in the outer carton in order to protect from light.
6.5
Nature and contents of container
Box of 1 x 5.5 ml multidose vials each containing 1.05 mg burserelin acetate per 1 ml, corresponding to 1.00 mg burserelin per 1 ml.
Pack size: 2 individual cardboard boxes are wrapped together in a clear plastic outer.
6.6 Special precautions for disposal
No special instructions.
7 MARKETING AUTHORISATION HOLDER
Aventis Pharma Limited
One Onslow Street
Guildford
Surrey
GU1 4YS
UK
or trading as:-
Sanofi-aventis or Sanofi
One Onslow Street
Guildford
Surrey
GU1 4YS
UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 04425/0268
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION 03/03/1986 / 27/02/2004
19/02/2015